Back to results
US 9,550,837 B2Granted
Therapeutic uses of anti-PCSK9 antibodies
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
Life of this patent
Estimating the term…
Abstract
An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
Claims10
A method for treating a subject selected from the group consisting of:
- a subject indicated for LDL apheresis, a subject with a PCSK9 gain of function mutation, and a subject with primary hypercholesterolemia who is statin intolerant or statin uncontrolled, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof which specifically binds hPCSK9, wherein the antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs:90/92 and 218/226.
Dependencies are inferred from the claim text.